Biogen Inc. has been planning to diversify its neuroscience R&D efforts by moving into neuropsychiatric indications, and on March 12 it made a start on that by acquiring the stalled AMPA receptor potentiator PF-04958242 from Pfizer Inc. for the unmet medical need of cognitive impairment associated with schizophrenia.
Pfizer advanced the first-in-class oral candidate into Phase II in schizophrenia previously, but set the molecule aside in 2016 before announcing earlier this year that it was exiting neuroscience discovery and development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?